PH12017500239A1 - Abiraterone acetate formulation and methods of use - Google Patents
Abiraterone acetate formulation and methods of useInfo
- Publication number
- PH12017500239A1 PH12017500239A1 PH12017500239A PH12017500239A PH12017500239A1 PH 12017500239 A1 PH12017500239 A1 PH 12017500239A1 PH 12017500239 A PH12017500239 A PH 12017500239A PH 12017500239 A PH12017500239 A PH 12017500239A PH 12017500239 A1 PH12017500239 A1 PH 12017500239A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- abiraterone acetate
- acetate formulation
- formulation
- compositions
- Prior art date
Links
- 229960004103 abiraterone acetate Drugs 0.000 title abstract 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052294P | 2014-09-18 | 2014-09-18 | |
| US14/707,922 US20150246060A1 (en) | 2013-03-15 | 2015-05-08 | Abiraterone Acetate Formulation and Methods of Use |
| PCT/US2015/050889 WO2016044701A1 (en) | 2014-09-18 | 2015-09-18 | Abiraterone acetate formulation and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12017500239A1 true PH12017500239A1 (en) | 2017-07-03 |
Family
ID=55533897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12017500239A PH12017500239A1 (en) | 2014-09-18 | 2017-02-09 | Abiraterone acetate formulation and methods of use |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3193857A4 (enExample) |
| JP (1) | JP2017528457A (enExample) |
| KR (2) | KR102491439B1 (enExample) |
| CN (1) | CN106687112A (enExample) |
| AP (1) | AP2017009804A0 (enExample) |
| AU (1) | AU2015317466A1 (enExample) |
| BR (1) | BR112017003219A2 (enExample) |
| CA (1) | CA2958316A1 (enExample) |
| CO (1) | CO2017002472A2 (enExample) |
| EA (1) | EA201790650A1 (enExample) |
| IL (1) | IL250270B (enExample) |
| MD (1) | MD20170048A2 (enExample) |
| MX (1) | MX2017003525A (enExample) |
| PH (1) | PH12017500239A1 (enExample) |
| SG (1) | SG11201701139YA (enExample) |
| TN (2) | TN2017000098A1 (enExample) |
| WO (1) | WO2016044701A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3280448B1 (en) | 2015-04-10 | 2020-12-30 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| WO2018187728A1 (en) | 2017-04-07 | 2018-10-11 | Maa Laboratories, Inc. | Methods of improving the solubility and bioavailability of therapeutic agents |
| EP3914234A4 (en) * | 2019-01-25 | 2022-09-14 | Shenzhen Pharmacin Co., Ltd. | PHARMACEUTICAL COMPOSITIONS |
| DK3935068T3 (da) | 2019-03-06 | 2023-12-04 | Propella Therapeutics Inc | Abirateron-prodrugs |
| CN110742870B (zh) * | 2019-12-04 | 2021-04-20 | 武汉大学 | 醋酸阿比特龙制剂及其制备方法 |
| CN111110646A (zh) * | 2020-02-19 | 2020-05-08 | 纳兰迦(上海)生物医药科技有限公司 | 一种低规格醋酸阿比特龙口服制剂的处方及制备方法 |
| CN113384542B (zh) * | 2020-03-14 | 2024-03-29 | 鲁南制药集团股份有限公司 | 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法 |
| US20230158047A1 (en) * | 2020-04-16 | 2023-05-25 | Tavanta Therapeutics Hungary Incorporated | Methods and compositions for treating prostate cancer |
| WO2021224471A1 (en) * | 2020-05-08 | 2021-11-11 | Janssen Pharmaceutica Nv | Pharmaceutical formulations of abiraterone acetate and niraparib |
| EP3944860A1 (en) | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abiraterone for use in a method of treating cancer |
| WO2022174134A1 (en) | 2021-02-15 | 2022-08-18 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| KR20240044329A (ko) | 2022-09-28 | 2024-04-04 | 한미약품 주식회사 | 아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제 |
| KR20240145412A (ko) | 2023-03-27 | 2024-10-07 | 한미약품 주식회사 | 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ595984A (en) * | 2009-04-24 | 2014-04-30 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
| GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
| WO2014009437A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Oxidation stability of abiraterone acetate |
| WO2014009434A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
| CN102743393A (zh) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | 一种含有醋酸阿比特龙的药物组合物及制备工艺 |
| CN105246598B (zh) * | 2013-03-15 | 2019-09-13 | 太阳药业环球公司 | 乙酸阿比特龙酯制剂 |
-
2015
- 2015-09-18 MD MDA20170048A patent/MD20170048A2/ro not_active Application Discontinuation
- 2015-09-18 KR KR1020177008938A patent/KR102491439B1/ko active Active
- 2015-09-18 CN CN201580050453.8A patent/CN106687112A/zh active Pending
- 2015-09-18 TN TN2017000098A patent/TN2017000098A1/en unknown
- 2015-09-18 SG SG11201701139YA patent/SG11201701139YA/en unknown
- 2015-09-18 WO PCT/US2015/050889 patent/WO2016044701A1/en not_active Ceased
- 2015-09-18 AU AU2015317466A patent/AU2015317466A1/en not_active Abandoned
- 2015-09-18 BR BR112017003219A patent/BR112017003219A2/pt not_active IP Right Cessation
- 2015-09-18 TN TNP/2018/000318A patent/TN2018000318A1/en unknown
- 2015-09-18 EP EP15842591.8A patent/EP3193857A4/en not_active Withdrawn
- 2015-09-18 CA CA2958316A patent/CA2958316A1/en active Pending
- 2015-09-18 AP AP2017009804A patent/AP2017009804A0/en unknown
- 2015-09-18 JP JP2017512783A patent/JP2017528457A/ja active Pending
- 2015-09-18 MX MX2017003525A patent/MX2017003525A/es unknown
- 2015-09-18 EA EA201790650A patent/EA201790650A1/ru unknown
- 2015-09-18 KR KR1020237001893A patent/KR102617537B1/ko active Active
-
2017
- 2017-01-25 IL IL250270A patent/IL250270B/en active IP Right Grant
- 2017-02-09 PH PH12017500239A patent/PH12017500239A1/en unknown
- 2017-03-15 CO CONC2017/0002472A patent/CO2017002472A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102491439B1 (ko) | 2023-01-25 |
| MX2017003525A (es) | 2017-06-21 |
| KR102617537B1 (ko) | 2023-12-22 |
| EP3193857A1 (en) | 2017-07-26 |
| SG11201701139YA (en) | 2017-03-30 |
| AU2015317466A1 (en) | 2017-02-23 |
| KR20230014878A (ko) | 2023-01-30 |
| MD20170048A2 (ro) | 2017-08-31 |
| JP2017528457A (ja) | 2017-09-28 |
| CO2017002472A2 (es) | 2017-07-11 |
| BR112017003219A2 (pt) | 2017-11-28 |
| AP2017009804A0 (en) | 2017-03-31 |
| IL250270B (en) | 2021-02-28 |
| IL250270A0 (en) | 2017-03-30 |
| CA2958316A1 (en) | 2016-03-24 |
| EP3193857A4 (en) | 2018-04-11 |
| TN2017000098A1 (en) | 2018-10-19 |
| CN106687112A (zh) | 2017-05-17 |
| WO2016044701A1 (en) | 2016-03-24 |
| KR20170070025A (ko) | 2017-06-21 |
| TN2018000318A1 (en) | 2020-01-16 |
| EA201790650A1 (ru) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500239A1 (en) | Abiraterone acetate formulation and methods of use | |
| ZA202004557B (en) | Modulatory polynucleotides | |
| NZ712350A (en) | Abiraterone acetate formulation | |
| PL3224254T3 (pl) | Podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków | |
| EP4620519A3 (en) | Methods and compositions relating to chondrisomes from blood products | |
| MY187540A (en) | Compounds active towards bromodomains | |
| IL273300A (en) | High dose valbenazine formulation and related preparations, methods and kits | |
| IL253793B (en) | Abiraterone acetate complexes, a process for their preparation and pharmaceutical preparations containing them | |
| EP3177271A4 (en) | Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof | |
| MX2020004205A (es) | Composiciones antibioticas de ceftolozano. | |
| IN2014MU00303A (enExample) | ||
| EP3093023A4 (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| EP3177286A4 (en) | Compositions and methods for physiological delivery using cannabidiol | |
| IN2014CH00840A (enExample) | ||
| EP3151826A4 (en) | Omega-3 compositions, dosage forms, and methods of use | |
| EP3175851A4 (en) | Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition | |
| HK1262230A1 (en) | Compositions and methods for delivery of therapeutic agents | |
| HK1239552A1 (en) | Compositions and method for physiological delivery using cannabidiol | |
| HK1234671A1 (en) | Omega-3 compositions, dosage forms, and methods of use | |
| GB201414271D0 (en) | Composition for delivery of an active pharmaceutical substance and method of preparing same | |
| MY180947A (en) | Ceftolozane antibiotic compositions | |
| IN2014CH01890A (enExample) |